Barbara Carreira

Graphical Abstract Nanovaccine In article number 2404159, Helena F. Florindo, Ronit Satchi-Fainaro, and co-workers describe the development of a next-generation thermostable multi-epitope mannosylated nanovaccine administered intranasally. This innovative nanovaccine generates mucosal immunity while regulating PD-1/PD-L1 axis within the DC-T cell interface, coordinating CD4 and CD8 T-cell immunities and activating robust neutralizing antibody responses against SARS-CoV-2.

1 Introduction Nanotechnology-based vaccines were at the forefront of the coronavirus disease of 2019 (COVID-19) vaccination campaign, with ≈13.59B doses administered globally.[1] These vaccines have played a paramount role against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection[2] by enabling rapid scale-up production and manufacturing of a synthetic vaccine while controlling the severity of the disease.[3] So far, all nanoplatforms approved as COVID-19 vaccines by the...

1 Introduction Breast cancer is a multifactorial disease, which incidence is expected to increase by 40% in 2040.[1] Among the different breast cancer subtypes, triple-negative breast cancer (TNBC) is the most aggressive, and accounts for 15% to 20% of all breast cancer cases, being typically observed in young women.[2] Since TNBC does not express hormone receptors nor the human epidermal growth factor receptor 2 (HER2),[2] the effective therapeutic options available are very limited.